We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Normalized Trading Activity to Aid BofA's (BAC) Q2 Earnings
Read MoreHide Full Article
Client activity seems to have returned to normalized levels, following the significant volatility recorded in the first quarter. Therefore, this will likely result in relatively stable trading revenues for Bank of America (BAC - Free Report) in second-quarter 2018. As trading revenues constitute a substantial part of the bank’s top line, this is expected to lend support to its results scheduled on Jul 16.
Unlike the first quarter when higher inflation expectation, tightening of monetary policy by the Fed, impending U.S.-China trade war and a sharp sell-off in the tech sector incited volatility, developments like further escalation in the trade war and some other geo-political tensions in the second quarter were not enough to lead to substantial rise in client activity.
Also, similar to the prior quarters, equity trading revenues are expected to render support to the total trading revenues in the to-be-reported quarter.
Further, at an investors’ conference in May, BofA CEO Brian Moynihan stated that the company’s trading income is expected to be flat year over year in the second quarter.
Nonetheless, the Zacks Consensus Estimate for Global Markets segment (under which trading revenues are accounted for) revenues of $4.12 billion indicates a decline of 14% from the prior quarter.
Overall Earnings & Revenue Growth Expectations
Notably for BofA, the Zacks Consensus Estimate for earnings of 56 cents reflects a 21.7% increase on a year-over-year basis. However, the consensus estimate for sales of $22.5 billion indicates a 1.5% decrease from the prior-year quarter.
Bank of America Corporation Price and EPS Surprise
Click here to know about the other factors that are likely to influence BofA’s overall results.
Conclusion
Stabilizing trading revenues are expected to benefit this Zacks Rank #3 (Hold) stock’s revenue growth (to some extent) in the second quarter. Also, decent loan growth and modest investment banking performance are likely to render support, while dismal mortgage banking performance is expected to somewhat hamper growth.
Other companies like Citigroup (C - Free Report) , JPMorgan (JPM - Free Report) and Morgan Stanley (MS - Free Report) expected to report flat to slight rise in trading revenues in the to-be-reported quarter.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Normalized Trading Activity to Aid BofA's (BAC) Q2 Earnings
Client activity seems to have returned to normalized levels, following the significant volatility recorded in the first quarter. Therefore, this will likely result in relatively stable trading revenues for Bank of America (BAC - Free Report) in second-quarter 2018. As trading revenues constitute a substantial part of the bank’s top line, this is expected to lend support to its results scheduled on Jul 16.
Unlike the first quarter when higher inflation expectation, tightening of monetary policy by the Fed, impending U.S.-China trade war and a sharp sell-off in the tech sector incited volatility, developments like further escalation in the trade war and some other geo-political tensions in the second quarter were not enough to lead to substantial rise in client activity.
Also, similar to the prior quarters, equity trading revenues are expected to render support to the total trading revenues in the to-be-reported quarter.
Further, at an investors’ conference in May, BofA CEO Brian Moynihan stated that the company’s trading income is expected to be flat year over year in the second quarter.
Nonetheless, the Zacks Consensus Estimate for Global Markets segment (under which trading revenues are accounted for) revenues of $4.12 billion indicates a decline of 14% from the prior quarter.
Overall Earnings & Revenue Growth Expectations
Notably for BofA, the Zacks Consensus Estimate for earnings of 56 cents reflects a 21.7% increase on a year-over-year basis. However, the consensus estimate for sales of $22.5 billion indicates a 1.5% decrease from the prior-year quarter.
Bank of America Corporation Price and EPS Surprise
Bank of America Corporation Price and EPS Surprise | Bank of America Corporation Quote
Click here to know about the other factors that are likely to influence BofA’s overall results.
Conclusion
Stabilizing trading revenues are expected to benefit this Zacks Rank #3 (Hold) stock’s revenue growth (to some extent) in the second quarter. Also, decent loan growth and modest investment banking performance are likely to render support, while dismal mortgage banking performance is expected to somewhat hamper growth.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Trading Revenue Projections for Other Companies
Other companies like Citigroup (C - Free Report) , JPMorgan (JPM - Free Report) and Morgan Stanley (MS - Free Report) expected to report flat to slight rise in trading revenues in the to-be-reported quarter.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>